# Combivent vs. Salbutamol in Patients With Metacholine Induced Bronchospasm

> **NCT02182713** · PHASE4 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 30 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Salbutamol sulfate/Ipratropium bromide
- **DRUG:** Salbutamol

## Key facts

- **NCT ID:** NCT02182713
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-05
- **Primary completion:** 1998-09
- **Final completion:** —
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2014-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02182713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02182713, "Combivent vs. Salbutamol in Patients With Metacholine Induced Bronchospasm". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02182713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*